Pharmacological effects of H 56-28: a new  -antagonist on the cardiovascular system.
D000255:Adenosine Triphosphate / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000498:Allyl Compounds / Q000494:pharmacology; D000605:Amino Alcohols / Q000494:pharmacology*; D000818:Animals; D001011:Aorta; D001158:Arteries; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D003864:Depression, Chemical; D004285:Dogs; D004554:Electric Countershock; D006321:Heart / Q000187:drug effects; D006325:Heart Atria / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption; D010636:Phenols / Q000494:pharmacology; D010725:Phosphocreatine / Q000378:metabolism; D011433:Propranolol / Q000627:therapeutic use; D011674:Pulse / Q000187:drug effects; D012039:Regional Blood Flow / Q000187:drug effects; D013566:Sympathomimetics / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000628:therapy
D000318:Adrenergic beta-Agonists; D000498:Allyl Compounds; D000605:Amino Alcohols; D010636:Phenols; D013566:Sympathomimetics; D010725:Phosphocreatine; D000255:Adenosine Triphosphate; D011433:Propranolol